Insider Selling: Intrexon Corp (XON) SVP Sells $1,152,610.00 in Stock

Intrexon Corp (NYSE:XON) SVP Joel D. Liffman sold 79,000 shares of Intrexon stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $14.59, for a total transaction of $1,152,610.00. Following the transaction, the senior vice president now directly owns 79,500 shares in the company, valued at approximately $1,159,905. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of NYSE:XON opened at $13.95 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. Intrexon Corp has a 1-year low of $10.26 and a 1-year high of $20.16. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -15.90 and a beta of 1.09.

Intrexon (NYSE:XON) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.28). Intrexon had a negative net margin of 82.17% and a negative return on equity of 16.67%. The firm had revenue of $45.30 million for the quarter, compared to analysts’ expectations of $51.70 million. During the same period in the prior year, the firm earned ($0.16) EPS. On average, equities research analysts predict that Intrexon Corp will post -0.79 EPS for the current fiscal year.

Several equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Intrexon from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Thursday, August 16th. JMP Securities lifted their price target on shares of Intrexon from $42.00 to $43.00 and gave the company a “market outperform” rating in a report on Wednesday, October 10th. ValuEngine raised shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Stifel Nicolaus assumed coverage on shares of Intrexon in a report on Tuesday, July 17th. They set a “buy” rating and a $72.00 price target on the stock. Finally, Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target on the stock. in a report on Monday, July 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.67.

Large investors have recently modified their holdings of the business. BB&T Securities LLC bought a new stake in shares of Intrexon during the second quarter valued at approximately $175,000. Chessman Wealth Strategies RIA bought a new stake in shares of Intrexon during the second quarter valued at approximately $205,000. Verition Fund Management LLC bought a new stake in shares of Intrexon during the first quarter valued at approximately $223,000. Bayesian Capital Management LP bought a new stake in shares of Intrexon during the first quarter valued at approximately $236,000. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Intrexon by 477.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 23,140 shares of the biotechnology company’s stock valued at $323,000 after buying an additional 19,136 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply